Announced
Financials
Sources
Tags
Private Equity
Private
Friendly
Biotechnology
Acquisition
Minority
Venture Capital
Single Bidder
China
Cross Border
Completed
biotechnology company
Synopsis
Investment firms Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec led a $200m Series A round in D3 Bio, a global biotechnology company focused on developing and commercializing precision medicines. "Our mission at D3 Bio is to build a global biotechnology company that develops innovative and more efficacious medicines for patients worldwide. The financing and support of our approach by reputable institutional investors give us a great start as we begin our journey to transform drug development to accomplish our mission," George Chen, D3 Bio Co-Founder, Chairman and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.